Researchers
at the University of Basel in Switzerland have found a way to transform breast
cancer cells into fat cells by exploiting a pivotal moment in their life-cycle.
At least, they have in mice.
The success
of the technique, published in the journal Cancer Cell, hinges on a process
called epithelial-mesenchymal transition (EMT).
In response
to cues in their microenvironment, epithelial cells reach a state of high
plasticity, enabling them to convert into a different type of cell. At this
stage, EMT, the cell resembles something close to a stem cell.
The process
is essential to various physiological mechanisms, including embryonic
development and wound healing. But, unfortunately, it also has some less benign
results. Cancer cells use EMT and its reverse process (mesenchymal-epithelial
transition, or MET) to travel from one part of the body to another. This allows
cancer to spread to different organs and different tissues – hence, primary and
secondary cancer.
It does,
however, also give scientists an opportunity to target the cancer in a
vulnerable state. The idea here is that if you are to target the cancerous
cells in this state of high plasticity before they reach MET, it may be
possible to transform them to a less-malign state and, therefore, prevent the
development of a secondary cancer.
To see if
their suspicions were correct, the team at Basel used mice given human breast
cancer cells. The mice were given two doses of drugs already approved by the US
Food and Drug Administration (FDA), one a cancer inhibitor (trametinib) and the
second an anti-diabetic drug (rosiglitazone).
The results
have been extremely promising. Not only were they able to prevent the cancer
from spreading to other parts of the body (metastasizing) but they were also able
to quell the growth of the primary tumor by preventing cancer cells within that
tumor from multiplying. Aggressive cancer cells that detached from the primary
tumor to find new ground were instead turned into fat cells, putting them in a
state where they were unable to do the body much harm.
"The
breast cancer cells that underwent an EMT not only differentiated into fat
cells, but also completely stopped proliferating," first author Gerhard
Christofori, a professor of biochemistry at the University of Basel, said in a
statement. "As far as we can tell from long-term culture experiments, the
cancer cells-turned-fat cells remain fat cells and do not revert back to breast
cancer cells."
Of course,
right now, we only know this treatment works in mice. Its effectiveness in
humans is still unknown. It is also worth pointing out that it does not
transform all cancer cells, only those undergoing EMT during metastasization.
Which means even if and when it does become an option for patients, it will
most likely need to be used in conjunction with chemo, not instead of.
Next, the
researchers hope to look at how this technique can be used with existing
chemotherapies and whether it can be adopted for other cancers.
Comments
Post a Comment